

# ARTRYA™

Coronary Artery Disease. We see you.

## ASX ANNOUNCEMENT

29 March 2022

### ARTRYA OPENS US OPERATIONS IN LOS ANGELES

---

**Perth, Western Australia** – Australian medical technology company, Artrya Limited (ASX: AYA, **Artrya or the Company**) creator of the AI-based solution, Artrya Salix, that supports physicians in the diagnosis of coronary artery disease, today announces the formation of the Company's American subsidiary, Artrya USA Inc. (**Artrya USA**) with its headquarters in Los Angeles, California. Ted Schwab and Jory Tremblay have been employed as Co-CEOs of Artrya USA and will head up the Company's entry into the US market.

Artrya's core solution is Salix Coronary Anatomy – a fast and effective AI-based technology capable of analysing cardiac CT scans to illustrate a unique combination of coronary artery disease biomarkers, including components of high-risk plaque.

"This is an important strategic move in bringing Artrya Salix to the US and the strong health industry backgrounds of Ted and Jory will be of tremendous value," said Artrya Managing Director and Co-Founder, John Barrington AM.

"The United States market is significant with over US\$200 billion (A\$266b) spent every year on cardiovascular disease. Representing 34% of the global market, it is timely for Artrya to establish US operations and we are extremely fortunate to have two such qualified individuals leading our entrance into the US market."

Artrya Salix supports clinicians in the diagnosis of coronary artery disease by highlighting the presence and extent of atherosclerotic plaque on a 3D heart image. A comprehensive overview is produced within 15 minutes to assist the clinician in developing a patient report, aiding personalised and optimal treatment.

"Our advanced method of supporting cardiac diagnosis will change medicine," said Mr Schwab. "Its revolutionary speed of pinpointing cardiac imaging biomarkers will accelerate treatment and, through partnership with clinicians, has the potential to save lives."

Mr Schwab has 35 years of health care industry experience has focused largely on strategy and business development.

"Artrya is in a unique position to bring the US market a truly innovative product," says Mr Tremblay. "As we form our clinical advisory board and solicit partnerships, Artrya's state-of-the-art technology will be recognised as a ground-breaking tool to aid cardiac diagnosis."

Mr Tremblay is an entrepreneur, strategist and technology go-to-market expert. Successful in corporate and digital start up settings in US and emerging markets, he brings 30 years of market assessment and scalability expertise as an investor, entrepreneur and advisor to management.

In their roles as Artrya US CEOs, the two will guide Artrya's launch in the US, including the development of its US strategy, clinical research partnerships and go to market approach.

Plans are progressing well with a significant medical group in the USA for retrospective clinical trials and a contract is expected within the coming weeks.

Artrya continues to engage with the Food and Drug Administration in the US and we believe that FDA approval remains on track for mid this year as previously advised to shareholders.

The announcement follows the January appointment of renowned healthcare executive Dr. Jacque J. Sokolov as Chair of Artrya's Clinical Advisory Board. Market clearance applications for Salix Coronary Anatomy (SCA) are currently under review with health authority regulators in the USA (FDA), Canada (Health Canada), Europe (CE Mark) and the UK (UKCA).

*This announcement was approved by the Company's Managing Director, John Barrington, on behalf of the Artrya Board.*

**For further information please contact:**

**Investor Enquiries:**

John Barrington  
Artrya Limited  
+61 419 850 502  
investors@artrya.com

**Media Enquiries:**

Felicity Heath  
Daymark  
+61 457 196 603  
felicity.heath@daymark.com.au

**About Artrya**

Based in Perth, Western Australia, Artrya was founded in 2018 and commenced operations in early 2019. Artrya Ltd is listed on the Australian Securities Exchange (ASX: AYA).

Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of a patient at risk. The Company has developed deep learning algorithms that will allow for the prediction and prevention of acute coronary events.

For more information, see [www.artrya.com](http://www.artrya.com)